Tag Archives: Vutrisiran

Amgen MariTide Ph2 Topline Results; Alnylam sNDA Accepted for Vutrisiran with PRV; Novartis Investor Event

Three cardiometabolic-related news items have been observed: Amgen announced topline 52-week data from its Ph2 MariTide obesity study (view press release); Alnylam announced FDA accepted the vutrisiran sNDA for the treatment of ATTR-CM with a PDUFA date on March 25, 2025 (view press release); and Novartis recently hosted a “Meet the Management” investor day (view press release; CEO presentation; breakout slides). Below, FENIX provides highlights and insights for the respective news items, including thoughts on Amgen’s placement in the obesity treatment paradigm.

This content is for Read Less members only.

Already a member? Log in here

Novo Semaglutide MASH Data; Abbott GLP-1RA Adherence Study; Alnylam and Regeneron Q3 ’24 Earnings

A series of cardiometabolic-related news items have been observed from Novo Nordisk, Abbott, Alnylam, and Regeneron. Below, FENIX provides highlights and insights for the respective news items.

This content is for Read Less members only.

Already a member? Log in here

Abbott Q3 ’24 Earnings; Neurogastrx’s NG101 Reduces GLP-1RA-Related AEs; Kaleido Insulin Pump Receives CE Mark; Alnylam Submits Vutrisiran to EMA

A series of cardiometabolic-related news items have been observed from Abbott, Neurogastrx, ViCentra, and Alnylam Pharmaceuticals. Below, FENIX provides highlights and insights for the respective news items.

This content is for Read Less members only.

Already a member? Log in here

Zealand Receives Second CRL; Lilly Partners for Drug Discovery and Peptide R&D; Alnylam Submits Vutrisiran sNDA; BI Initiates Two Survodutide Trials

A series of cardiometabolic-related news items have been observed from Zealand Pharma, Lilly, Alnylam Pharmaceuticals, and Boehringer Ingelheim. Below, FENIX provides highlights and insights for the respective news items.

This content is for Read Less members only.

Already a member? Log in here

Novo Initiates Ph1 Study for New Obesity Asset; Lemonaid GLP-1RA and Compounded Semaglutide Program; New Semaglutide HF Analysis Published; Alnylam’s Ph3 ATTR-CM Vutrisiran Data

A series of cardiometabolic-related news items have been observed from Novo Nordisk, Lemonaid Health, and Alnylam Pharmaceuticals. Below, FENIX provides highlights and insights for the respective news items.

This content is for Read Less members only.

Already a member? Log in here

Tirzepatide SUMMIT HFpEF Topline Results; Regeneron, Alnylam, Ionis, Teladoc, Amarin, and Biomea Q2 ’24 Earnings; Antag Increases Series A Funding for GIP Antagonism; Sanofi Expands Insulin Manufacturing in Germany; Boston Pharmaceuticals MASH Updates

A series of cardiometabolic-related news items have been observed from Lilly, Regeneron, Alnylam, Antag Therapeutics, Sanofi, Boston Pharmaceuticals, Ionis, Teladoc, Amarin, and Biomea Fusion. Below, FENIX provides highlights and insights for the respective news items, including initial thoughts on Lilly’s tirzepatide HFpEF results in the context of Novo’s STEP HFpEF and apparent regulatory delay.

This content is for Read Less members only.

Already a member? Log in here